4//SEC Filing
Bellinger Andrew 4
Accession 0001209191-22-059438
CIK 0001840574other
Filed
Dec 1, 7:00 PM ET
Accepted
Dec 2, 5:00 PM ET
Size
5.0 KB
Accession
0001209191-22-059438
Insider Transaction Report
Form 4
Bellinger Andrew
Chief Scientific Officer
Transactions
- Sale
Common Stock
2022-12-01$22.95/sh−865$19,852→ 6,629 total
Footnotes (1)
- [F1]Represents shares acquired pursuant to the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan on November 30, 2022 in a transaction exempt pursuant to Rule 16b-3(c). The shares were automatically sold through an automatic sale program in which the Reporting Person elected to participate on May 1, 2022. The sale does not represent a discretionary trade by the Reporting Person.
Documents
Issuer
Verve Therapeutics, Inc.
CIK 0001840574
Entity typeother
Related Parties
1- filerCIK 0001864116
Filing Metadata
- Form type
- 4
- Filed
- Dec 1, 7:00 PM ET
- Accepted
- Dec 2, 5:00 PM ET
- Size
- 5.0 KB